BEST TRIAL

BEST TRIAL

A trial comparing long-term clinical and angiographic results of the BeStent and Palmaz-Schatz stent in native coronary lesions.
 
Primary endpoints
6-month major acute coronary events (MACE).
 
Conclusion
The BeStent is at least as safe and effective as the Palmaz-Schatz, with lower rates of target vessel and target lesion revascularisation; both cohorts had binary restenosis rates comparable to other stents.